HCP Access Only

Dupixent approved in Singapore as the first-ever biologic medicine for patients with COPD

Singapore, 14 May 2025 – The Health Sciences Authority (HSA) has approved Dupixent (dupilumab) for adults as an add-on maintenance treatment for uncontrolled chronic obstructive pulmonary disease (COPD) characterized by raised blood eosinophils who are on a stable combination of an inhaled corticosteroid (ICS), a long-acting beta2-agonist (LABA), and a long-acting muscarinic antagonist (LAMA), or on a combination of a LABA and a LAMA if ICS is not appropriate.

Log In or Register as a healthcare professional to read the full article.

Copyright © Medical Channel Asia 2024. All rights reserved.
The contents on Medical Channel Asia are for general educational purposes only.
It is not intended to be a substitute for professional medical advice, treatment, or diagnosis.
See additional information.

Don’t have an account? Click here to register

[ultimatemember form_id="29399"]

If have account, Click here to login